Equity Profile

BMRN

BioMarin Pharmaceutical Inc.

Health CareBiotechnology$11.1B

Aug3Mon

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.78

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases. With a market cap of $11 billion, it plays a crucial role in the healthcare sector by addressing unmet medical needs and improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly missing expectations. The stock reacted positively, gaining 2.59% the following day.

Management Promises & Guidance

Focus on advancing key therapies in the pipeline.
Commitment to improving operational efficiency.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Overall, analysts expect a cautious outlook for BioMarin as it navigates challenges in meeting earnings expectations.

Bull Case

If the company can showcase strong revenue growth and positive updates on its product pipeline, it could lead to a significant stock rally.

Bear Case

Conversely, if the company fails to meet EPS expectations again or provides weak guidance, it could lead to a decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.78

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue Growth

N/A

Revenue growth is vital for assessing the company's ability to expand its market presence and sustain operations.

Product Pipeline Updates

N/A

Updates on the product pipeline can indicate future revenue potential and the company's innovation capabilities.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated guidance for EPS and revenue growth for the upcoming quarters?

This guidance will provide insight into the company's financial health and growth trajectory, which is critical for investor confidence.

What progress has been made on the product pipeline, particularly any upcoming launches?

Updates on the product pipeline can significantly impact future revenue and market position, making this a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin's product pipeline to deliver stronger-than-expected results, particularly given recent advancements.

Supporting Evidence

The company has a history of beating EPS expectations, with a 75% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders expect volatility, which may not align with conservative earnings expectations.

Key Risk

If the product pipeline shows significant progress, it could lead to a reevaluation of growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for growth against recent earnings misses and operational challenges.

Bull Confirmed If

A reported EPS of $0.80 or higher, along with positive updates on the product pipeline, would confirm the bull case.

Bear Confirmed If

An EPS below $0.70 or negative commentary on the product pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations with strong EPS and positive guidance, history suggests the stock could see a modest uptick of around 2.36%.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may remain flat or see slight downward pressure.

Miss

Should the company miss on EPS, history indicates a potential decline of about 0.37%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any upcoming launches.
2Specific EPS and revenue guidance for the next quarter.
3Management's commentary on operational efficiency improvements.
4Insights into market access strategies for existing products.
5Any changes in competitive landscape or regulatory challenges.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug3

ONBMO

ON Semiconductor Corporation

PreviewView

Aug3

LBMO

Company Snapshot

BioMarin Pharmaceutical Inc. is a biotechnology company focused on developing innovative therapies for rare genetic diseases....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

$0.78

Revenue Growth

Revenue growth is vital for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

BMRN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+117.28%

Avg Stock Reaction

-0.49%

Last Quarter Recap

In Q1-2026, BioMarin reported an EPS of $0.76, slightly missing expectations. The stock reacted positively, gaining 2.59% the following day.

Management Promises & Guidance

Focus on advancing key therapies in the pipeline.
Commitment to improving operational efficiency.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Overall, analysts expect a cautious outlook for BioMarin as it navigates challenges in meeting earnings expectations.

Bull Case

If the company can showcase strong revenue growth and positive updates on its product pipeline, it could lead to a significant stock rally.

Bear Case

Conversely, if the company fails to meet EPS expectations again or provides weak guidance, it could lead to a decline in stock value.

Key Metrics to Watch

Earnings Per Share (EPS)

$0.78

EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.

Revenue Growth

N/A

Revenue growth is vital for assessing the company's ability to expand its market presence and sustain operations.

Product Pipeline Updates

N/A

Updates on the product pipeline can indicate future revenue potential and the company's innovation capabilities.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the updated guidance for EPS and revenue growth for the upcoming quarters?

This guidance will provide insight into the company's financial health and growth trajectory, which is critical for investor confidence.

What progress has been made on the product pipeline, particularly any upcoming launches?

Updates on the product pipeline can significantly impact future revenue and market position, making this a key focus for investors.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for BioMarin's product pipeline to deliver stronger-than-expected results, particularly given recent advancements.

Supporting Evidence

The company has a history of beating EPS expectations, with a 75% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders expect volatility, which may not align with conservative earnings expectations.

Key Risk

If the product pipeline shows significant progress, it could lead to a reevaluation of growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is currently weighing the potential for growth against recent earnings misses and operational challenges.

Bull Confirmed If

A reported EPS of $0.80 or higher, along with positive updates on the product pipeline, would confirm the bull case.

Bear Confirmed If

An EPS below $0.70 or negative commentary on the product pipeline would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±15.32%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings announcement.

Options are pricing ±15.3% while BMRN has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

42.3%

Calls (10K)P/C Ratio: 0.20Puts (4K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If BioMarin beats expectations with strong EPS and positive guidance, history suggests the stock could see a modest uptick of around 2.36%.

In-Line / Cautious

If results are in line with expectations but management provides cautious commentary, the stock may remain flat or see slight downward pressure.

Miss

Should the company miss on EPS, history indicates a potential decline of about 0.37%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the product pipeline and any upcoming launches.
2Specific EPS and revenue guidance for the next quarter.
3Management's commentary on operational efficiency improvements.
4Insights into market access strategies for existing products.
5Any changes in competitive landscape or regulatory challenges.